Dark

APVO
Aptevo Therapeutics Inc
stock NASDAQ

At Close

Dec 10, 2025 3:59:48 PM EST

1.20USD-3.226%(-0.04)8,181,727

1.19Bid 1.20Ask 0.01Spread

Pre-market

Dec 10, 2025 9:29:59 AM EST

1.28USD+3.226%(+0.04)353,714

After-hours

Dec 10, 2025 4:58:30 PM EST

1.17USD-2.475%(-0.03)49,617

OverviewHistoricalExchangesShortsNews

Jan 21, 2022

08:25AM EST Aptevo Therapeutics Board Appointed John Niederhuber, M.D. As Chairman Of The Board Effective April 1, 2022 Benzinga

08:24AM EST Aptevo Therapeutics Chairman Of Board Fuad El-Hibri Notified Co Of His Retirement, Resignation As A Director Of Co, Effective April 1, 2022 Benzinga

Dec 15, 2021

08:09AM EST Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication In Peer-Reviewed Journal, 'Nature Communication' Benzinga

Dec 14, 2021

04:45PM EST Aptevo Therapeutics On Monday Published 2 Poster Presentations Ahead Of American Society Of Hematology, 1 Poster For Cytokine Release Syndrome, 1 For Single Agent Anti-Neplastic Activity Benzinga

Nov 26, 2021

07:08AM EST The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.00 A.M. ET). RTTNews

Nov 24, 2021

09:18AM EST Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Nov. 24, 2021: KTTA, APVO, TSLA, BFRI, OCUP Benzinga

Nov 23, 2021

02:31PM EST Mid-Afternoon Market Update: Dow Surges 100 Points; Zoom Video Shares Plunge Benzinga

12:32PM EST Mid-Day Market Update: Nasdaq Tumbles Over 200 Points; Pasithea Therapeutics Shares Surge Benzinga

10:33AM EST Mid-Morning Market Update: Markets Mostly Lower; Best Buy Posts Upbeat Q3 Earnings Benzinga

08:25AM EST Aptevo Therapeutics Inc. Announces Clinical Update For Phase 1b Expansion Trial Evaluating APVO436; Prelim. Data Includes One Complete Remission Benzinga

Nov 15, 2021

11:14AM EST Aptevo Therapeutics Announces Presentation Of 2 Abstracts At Upcoming American Society Of Hematology Annual Meeting Benzinga

Nov 12, 2021

11:23AM EST Looking Into Aptevo Therapeutics's Return On Capital Employed Benzinga

08:24AM EST Aptevo Therapeutics Q3 EPS $(1.42) Up From $(2.15) YoY, Sales $3.10M Up From $1.46M YoY Benzinga

Nov 11, 2021

04:48PM EST Alligator Bioscience, Aptevo Therapeutics Announce Poster Presentation Of ALG.APV-527 At SITC Annual Meeting 2021 Benzinga

08:34AM EST Aptevo Highlights Presentation Of Preclinical Data For Bispecific Antibody APVO603 At Society For Immunology In Cancer Meeting Nov. 13, 2021 Benzinga

Nov 2, 2021

09:00AM EDT BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, is pleased to welcome the appointment of Jane Gross, Ph.D. to its Board of Directors. GlobeNewswire Inc

Oct 27, 2021

08:06AM EDT Aptevo Therapeutics Presents Clinical Data On Lead Leukemia Drug Candidate APVO436 At Second Virtual Conference On Controversies In Leukemias, Euroleuk2021 Benzinga

Oct 26, 2021

08:15AM EDT Aptevo Therapeutics Highlights Publication In Medical Journal Cancers That Risk Of Cytokine Release Syndrome Is Low For Blood Cancer Patients Treated With Its Bispecific Antibody APVO436 Benzinga

Sep 28, 2021

08:13AM EDT Aptevo Therapeutics Highlights Publication Of A Scientific Article In Peer-Reviewed Journal, Frontiers In Aging Benzinga

08:09AM EDT Aptevo Therapeutics Announces Publication Of Scientific Article In Peer-Reviewed Journal, Frontiers In Aging Benzinga

Aug 17, 2021

08:09AM EDT Aptevo Therapeutics Reports APVO436 Monotherapy Is Active In Patients Who Have Relapsed Acute Myeloid Leukemia Or Myelodysplastic Syndrome Benzinga

Aug 12, 2021

05:22PM EDT Aptevo Therapeutics Files Prospectus Related to Resale of Up to 1,250,000 Shares of the Common Stock Benzinga

08:29AM EDT Aptevo Therapeutics Q2 EPS $(1.75) Up From $(2.10) YoY Benzinga

Jul 22, 2021

12:40PM EDT Aptevo Therapeutics ClinicalTrials.gov Study Record Detail For Co.'s 'Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML', Not Yet Recruiting Benzinga

Jul 16, 2021

08:10AM EDT Aptevo Therapeutics Chief Scientific Officer Jane Gross, To Present At Upcoming Cambridge Health Institute PEGS Virtual Conference Jul. 19-22 Benzinga

Jun 21, 2021

03:27PM EDT Mid-Afternoon Market Update: Dow Jumps Over 500 Points; Lydall Shares Spike Higher Benzinga

10:10AM EDT Mid-Morning Market Update: Markets Open Higher; CNH Industrial To Buy Raven Industries Benzinga

Jun 18, 2021

10:22AM EDT Aptevo Therapeutics Insights: Return On Capital Employed Benzinga

Jun 4, 2021

10:50AM EDT Looking Into Aptevo Therapeutics's Return On Capital Employed Benzinga

May 28, 2021

08:35AM EDT Roth Capital Maintains Buy on Aptevo Therapeutics, Lowers Price Target to $50 Benzinga

May 27, 2021

09:01AM EDT Aptevo Therapeutics Announces Expansion Phase Of APVO436 In Adult Patients With Acute Myeloid Leukemia Benzinga

May 26, 2021

09:32AM EDT Aptevo Stock Gains on Encouraging Single-Agent Activity for APVO436 In Leukemia Patients Benzinga

09:09AM EDT Aptevo Therapeutics Reports Phase 1 Clinical Data For Leukemia Drug Candidate APVO436 In Adults With Relapsed Acute Myeloid Leukemia; Study Met Primary Endpoing Benzinga

May 11, 2021

09:06AM EDT Aptevo Therapeutics Q1 EPS $(1.64) Down From $0.89 YoY Benzinga

Apr 12, 2021

10:55AM EDT Watching Aptevo Shares Are Traders Circulate Co. Slide For American Association For Cancer Research Meeting Benzinga

Apr 9, 2021

09:02AM EDT Aptevo Therapeutics To Present At American Association For Cancer Research Virtual Annual Meeting; Co Will Provide Preclinical Updates On APVO603 And APVO442 Benzinga

Mar 31, 2021

08:37AM EDT Aptevo Therapeutics Provides 2020 Business Update (Full Statement) Benzinga

Feb 10, 2021

07:34AM EST The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga

Dec 14, 2020

08:58AM EST Aptevo Therapeutics Files For $200M Mixed Shelf Offering Benzinga

Nov 20, 2020

08:06AM EST The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger Benzinga

Nov 19, 2020

04:17PM EST Aptevo Confirms Confirms Receipt Of Unsolicited Non-Binding Indication Of Interest From Tang Capital Partners To Acquire All Aptevo Shares It Does Not Down For $50/Share In Cash; Co. Will 'carefully evaluate and consider this indication of interest' Benzinga

02:38PM EST Mid-Afternoon Market Update: Dow Turns Positive; Medigus Shares Spike Higher Benzinga

02:36PM EST Mid-Afternoon Market Update: S&P 500 Turns Positive; Medigus Shares Spike Higher Benzinga

12:17PM EST Mid-Day Market Update: Nasdaq Rises 50 Points; MeiraGTx Shares Plunge Benzinga

10:14AM EST Mid-Morning Market Update: Markets Mixed; Macy's Posts Narrower-Than-Expected Loss Benzinga

05:53AM EST What's moving these stocks in the pre-market hours today? RTTNews

Nov 18, 2020

05:11PM EST Tang Capital Partners Says We Are Pleased To Submit A Proposal To Acquire The Remaining Common Stock Of Aptevo Therapeutics That TCP Does Not Already Own For A Price Of $50/Share In Cash Benzinga

05:07PM EST Tang Capital Partners In 13D Filing Report 42.5% Stake In Aptevo Therapeutics Benzinga

Nov 16, 2020

01:06PM EST When To Follow Trend Benzinga

11:10AM EST RTW Investments Reports 8.97% Passive Stake In Aptevo Therapeutics Benzinga

08:26AM EST Aptevo Therapeutics, Alligator Biosciences Advancing The Bispecific 4-1BBx5T Antibody ALG.APV-527 Into Phase 1 Clinical Development Benzinga

Nov 11, 2020

09:02AM EST Piper Sandler Maintains Overweight on Aptevo Therapeutics, Raises Price Target to $69 Benzinga

Nov 10, 2020

05:03PM EST Aptevo Therapeutics Q3 EPS $(2.10) Benzinga

08:40AM EST The Daily Biotech Pulse: Lilly's COVID-19 Antibody Treatment Approved For Emergency Use, Supernus Faces Twin Regulatory Setbacks, Revance, Arena Flunk Midstage Studies Benzinga

Nov 9, 2020

04:02PM EST Why Aptevo's Stock Is Trading Higher Today Benzinga

02:30PM EST Mid-Afternoon Market Update: Dow Surges Over 1300 Points; Arcturus Therapeutics Shares Slide Benzinga

12:40PM EST Mid-Day Market Update: Crude Oil Jumps Over 9%; HighPoint Resources Shares Plummet Benzinga

10:57AM EST Aptevo Shares Relatively Quiet As Traders Circulate Word Roth Capital, Ladenburg Thalmann Raised Price Targets On Stock To $64 Benzinga

10:20AM EST Stocktwits Trending Stocks For Monday, Nov. 9, 2020: PFE, RKT, INO, CCL, AAL, SPG, NCLH, APVO, NLS, CODX Benzinga

10:15AM EST Mid-Morning Market Update: Markets Open Higher; Pfizer-BioNTech's COVID-19 Vaccine Candidate Is 90% Effective Benzinga

06:12AM EST Aptevo Therapeutics Says a 2nd Patient Showed Complete Remission in its Study for a Treatment for Acute Myeloid Leukemia Benzinga

05:25AM EST Tang Capital Partners Lp Reported Purchase of 1,436,675 Shares of Aptevo Therapeutics Inc. @ Avg Price: of $17.30/Share in a Form 4 Filing Late Friday Benzinga

05:20AM EST Aptevo Therapeutics Announced Limited Duration Stockholder Rights Plan Late Sunday After Tang Capital Partners Reported a 54.4% Stake on Friday Benzinga

Nov 6, 2020

09:17AM EST Tricky Trading Through The Election Benzinga

07:47AM EST The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold Benzinga

Nov 5, 2020

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

Nov 4, 2020

11:27AM EST Yahoo Finance Trending Stocks For Wednesday, Nov. 4, 2020: UBER, LYFT, AAPL, KODK, MSFT, FB, AMD, AMZN, NIO, TSLA, TQQQ, NVDA, QQQ, DRAD, GOOG, DKNG, RIDE, NFLX, FSLY, GOOGL, APVO, ZM, WKHS, ADBE, DOCU, SAVA, SQQQ, SMG Benzinga

10:24AM EST Mid-Morning Market Update: Markets Open Higher; Performance Food Earnings Top Views Benzinga

05:56AM EST What's moving these stocks in the pre-market hours today? RTTNews

Nov 3, 2020

11:44AM EST Why Aptevo's Stock Is Trading Higher Today Benzinga

10:10AM EST Shares of Aptevo Therapeutics Inc. (APVO) are gaining over 15% on Tuesday morning after the clinical-stage biotechnology company announced first complete remission in ongoing Phase 1 trial for blood cancer. RTTNews

09:03AM EST Aptevo Therapeutics Announces First Complete Remission Observed In Ongoing APVO436 Phase 1 Clinical Trial Benzinga

Sep 1, 2020

09:05AM EDT Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial Benzinga

Aug 14, 2020

09:14AM EDT Aptevo Therapeutics Q2 EPS $(2.10) Down From $(0.30) YoY, Sales $473.00K Down From $7.36M YoY Benzinga